Search Results
Your search for ,ITS matches 8694 pages
Showing 2951 - 3000The 21st Century Cures Act: A Look Back, a Look Ahead
It was ambitious and it was controversial, but the bipartisan 21st Century Cures Act (Cures) made it through both houses of Congress and was signed into law in December 2016. Sponsored by Representatives Diana DeGette (D-CO) and Fred Upton (R-MI), the landmark legislation funded new medical...
IMbrave150: A New Standard of Care to Treat Hepatocellular Cancers?
In 2007, sorafenib became the first approved systemic therapy for hepatocellular cancers and the first agent to improve overall survival in these patients.1 In a similar multikinase inhibitor strategy, lenvatinib was found to be noninferior to sorafenib in overall survival in the same patient...
FDA Collaborating on Use of Real-World Data to Inform COVID-19 Response Effort
On June 18, 2020, the U.S. Food and Drug Administration (FDA) took an additional step in harnessing real-world data to help inform the agency’s overall response to the COVID-19 public health emergency. The FDA announced its participation in the COVID-19 Diagnostics Evidence Accelerator, a...
A Palliative Care Specialist Explores What It Means to Live and Die With Dignity and Purpose
Palliative care’s road to acceptance as standard-of-care practice has been a remarkably unsmooth one, given its core mission: improving the quality of life of patients and their families by relieving the pain, symptoms, and stress of a serious or life-limiting illness. A person’s relationship with...
Expert Point of View: Ryan J. Sullivan, MD
The study’s invited discussant, Ryan J. Sullivan, MD, Assistant Professor of Medicine, Harvard Medical School, and Assistant Professor in Hematology/Oncology at Massachusetts General Hospital, welcomed the positive results from the updated analysis of lifileucel in treatment-refractory melanoma....
A Long-Time Student of Leadership, Brian J. Bolwell, MD, FACP, Ultimately Takes the Reins at the Taussig Cancer Institute
In this edition of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, interviewed his colleague Brian J. Bolwell, MD, FACP, Chairman of the Cleveland Clinic Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic. Among other things, Dr. Bolwell discussed his...
Expert Point of View: Suzanne Lentzsch, MD, PhD, and Joshua Richter, MD
Two myeloma specialists weighed in on the disappointing findings of SWOG S1211: Suzanne Lentzsch, MD, PhD, Professor of Medicine at Columbia University and Director of the Multiple Myeloma and Amyloidosis Service, and Joshua Richter, MD, Assistant Professor of Medicine, Icahn School of Medicine at...
Roundup of High-Impact Studies in Early Breast Cancer
Clinicians interested in breast cancer who logged into the ASCO20 Virtual Scientific Program were greeted with an abundance of high-impact presentations. The ASCO Post has reported on several studies in depth elsewhere, but here we offer our readers a roundup of several important studies in early...
Geriatric Assessment: What Are You Waiting For?
The ASCO20 Virtual Scientific Program was the forum for an unusual but profoundly important event in oncology. Four studies that should be practice-changing were presented.1-4 These studies provided irrefutable evidence that we can improve the quality of life of older patients by reducing toxicity. ...
Expert Point of View: Philip McCarthy, MD
Philip McCarthy, MD, Professor of Oncology and Internal Medicine and Director of the Transplant and Cellular Therapy Center at Roswell Park Comprehensive Cancer Center, Buffalo, New York, found the results of the DREAMM-6 study to be “exciting and promising.” He commented: “The overall response...
Responses Achieved With Belantamab Mafodotin in Relapsed or Refractory Myeloma
The antibody-drug conjugate belantamab mafodotin yielded responses as a single agent and in combination with bortezomib and dexamethasone in the treatment of relapsed or refractory multiple myeloma, according to two reports from the DREAMM team at the ASCO20 Virtual Scientific Program.1,2 In the...
AACR Recognizes New 2019–2020 Research Grantees
The American Association for Cancer Research (AACR) has announced its newest class of grant recipients. Fellowships The 2019 Anna D. Barker Fellowship in Basic Cancer Research was awarded to Chaoyun Pan, PhD, of Emory University, Atlanta, and Conghui Yao, PhD, of Harvard Medical School, Cambridge....
Lung Cancer Research Foundation Names Trudy Oliver, PhD, to Its Scientific Advisory Board
The Lung Cancer Research Foundation (LCRF) recently announced that Trudy Oliver, PhD, has joined its Scientific Advisory Board. Dr. Oliver is Associate Professor of Oncological Sciences at the University of Utah’s Huntsman Cancer Institute (HCI), where she has served since 2011, and is an HCI...
Phase II Study Evaluates Chemotherapy and Immunotherapy in Patients With Malignant Pleural Mesothelioma
Data from the phase II PrE0505 multicenter trial showed that adding durvalumab, an immune checkpoint antibody targeting programmed cell death ligand 1 (PD-L1), to the combination of cisplatin and pemetrexed chemotherapy improved outcomes in previously untreated patients with unresectable malignant...
A Visiting Resident Oncologist’s Training During the COVID-19 Pandemic
A visiting away elective is a resident’s designated time to visit another academic program to foster the growth of medical knowledge through patient care from the perspective of another health-care system and educational experience. The time dedicated to make this dream happen is grueling. First...
Understanding the Underlying Mechanisms of Pain in Patients With Cancer
Pain is among the most difficult medical issues for oncologists to confront, said Tony L. Yaksh, PhD, Professor of Anesthesiology and Pharmacology at the University of California, San Diego, during his keynote address at the 2019 Supportive Care in Oncology Symposium. Failure to adequately manage...
Improving the Quality of Care and Research for Patients With Cancer and the Ethics Behind Its Delivery
With the rapid expansion of scientific advances, the intersection of ethics and the delivery of cancer care becomes ever more complicated. To shed light on some of the challenging ethical issues faced by today’s busy oncology practitioners, The ASCO Post spoke with Rebecca D. Pentz, PhD, Professor ...
Donor Spotlight: GO2 Foundation for Lung Cancer Unifies to Drive Change
In 2019, the GO2 Foundation for Lung Cancer was born from the merger of the Bonnie J. Addario Lung Cancer Foundation and the Lung Cancer Alliance. The marriage of two lung cancer advocacy groups raises the profile of each group’s work and combines considerable resources to combat lung cancer. The...
Conquer Cancer Grants More Than $8 Million to Cancer Research
Conquer Cancer, the ASCO Foundation, announced its 2020 grant and award recipients in conjunction with the 2020 ASCO Virtual Scientific Program. The awards will support researchers with projects spanning many areas in cancer care, including immunotherapy, lung and breast cancers, and palliative...
Glenn D. Steele, Jr, MD, PhD, Named Chair of City of Hope Board of Directors
Health-care innovator and leader Glenn D. Steele Jr, MD, PhD, has been elected Board Chair at City of Hope. Dr. Steele joined the City of Hope Board of Directors in 2016 and was Chair of the Executive Compensation and Governance Committee from 2018 to 2020. “City of Hope has benefited from...
ASCO Opens Search for Chief Medical Officer: Express Interest by August 21, 2020
ASCO is conducting an open search for the position of Chief Medical Officer and Executive Vice President, as current Chief Medical Officer, Richard L. Schilsky, MD, FACP, FSCT, FASCO, prepares to retire in February 2021. ASCO’s Chief Medical Officer applies his/her medical and scientific knowledge ...
Insomnia in Adolescent and Young Adult Cancer Survivors
Adolescents and young adults (AYA) who have survived cancer may continue to suffer from insomnia long after treatment ends, interfering with a range of daily activities. In Pediatric Blood & Cancer, Eric S. Zhou, PhD, and Christopher J. Recklitis, PhD, MPH, of Dana-Farber Cancer Institute,...
Addressing Discrimination and Bias in Medical Education
“As a medical student, I often felt marginalized from my medical community. I have been told that my name is ‘not American,’ fallen prey to being confused for support staff such as a janitor (even while wearing my white coat), and been asked questions like, ‘Where are you really from?’ or ‘How old...
Jorge E. Cortes, MD, on Chronic Phase CML: Comparing Three Starting Doses of Ponatinib
Jorge E. Cortes, MD, of Georgia Cancer Center, discusses interim results from the OPTIC study, which showed a trend toward dose-dependent efficacy and safety, and may provide a refined understanding of the ponatinib benefit/risk profile and its relation to dose. Mature data from continued follow-up ...
PSMA-Targeted PET/CT Imaging May Be Useful in Biochemically Recurrent Prostate Cancer
Positron-emission tomography/computed tomography (PET/CT) imaging with the prostate-specific membrane antigen (PSMA)-targeted radiotracer fluorine F-18 DCFPyL (PyL) successfully identified areas of occult metastasis in men with biochemically recurrent metastatic castration-resistant prostate...
Expert Point of View: TROPHIMMUN Trial
Two gynecologic oncologists and ASCO’s Chief Medical Officer and Executive Vice President Richard L. Schilsky, MD, FACP, FSCT, FASCO, commented on the findings of the TROPHIMMUN trial for The ASCO Post. “The authors demonstrate efficacy of a new treatment approach for gestational trophoblastic...
Alpelisib Deemed Effective in Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor
The phase II BYLieve trial indicates the effectiveness of the PIK3CA inhibitor alpelisib in patients with PIK3CA-positive, hormone receptor–positive/HER2-negative advanced breast cancer previously treated with a cyclin-dependent kinase (CDK) 4/6 inhibitor plus an aromatase inhibitor. These results...
Expert Point of View: Philip McCarthy, MD
Philip McCarthy, MD, Professor of Oncology and Internal Medicine and Director of the Transplant and Cellular Therapy Center at Roswell Park Comprehensive Cancer Center, Buffalo, New York, found the results of the DREAMM-6 study to be “exciting and promising.” He commented: “The overall response...
Belantamab Mafodotin Shows Activity in Relapsed or Refractory Myeloma
Treatment of relapsed or refractory multiple myeloma yielded responses with the antibody-drug conjugate belantamab mafodotin, both as a single agent and in combination with bortezomib and dexamethasone. Two reports from the DREAMM team expanded on these findings at the ASCO20 Virtual Scientific...
Expert Point of View: Axel Grothey, MD
Sharing his perspective on KEYNOTE-177 with The ASCO Post was Axel Grothey, MD, Director of GI Cancer Research at the West Cancer Center, OneOncology, Memphis. “This is a very important, highly anticipated study,” he said. “It’s the first randomized trial of any checkpoint inhibitor in...
Rates of Progression-Free Survival in MSI-H/dMMR Metastatic Colorectal Cancer Doubled by Pembrolizumab
Upfront treatment with immunotherapy not only improved results in a subset of patients with metastatic colorectal cancer, it doubled the rates of median progression-free survival. These findings—the first of their kind—arose from the interim analysis of the randomized open-label phase III...
Advanced Bladder Cancer Survival Improved With Maintenance Avelumab
According to an interim analysis of the phase III JAVELIN Bladder 100 trial, rates of survival among patients with advanced urothelial carcinoma who did not progress on first-line platinum-based chemotherapy were significantly prolonged by maintenance therapy with avelumab and best supportive care...
Expert Point of View: Lecia V. Sequist, MD
Lecia V. Sequist, MD, who was not involved in the ADAURA study, said this could be a practice-changing study. Dr. Sequist is the Landry Family Professor of Medicine at Harvard Medical School and Director of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital....
Conference Highlights From the ASCO20 Virtual Scientific Program
The global outbreak of the COVID-19 pandemic forced many cancer societies, including ASCO, to cancel their in-person meetings this year and instead present the latest advancements and new approaches in oncology care via a virtual platform. For the first time in its 56-year history, the ASCO Annual...
FDA Pipeline: Agents for the Treatment of Prostate and Pancreatic Cancers, Marginal Zone Lymphoma
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to relugolix for the treatment of advanced prostate cancer; Fast Track designation to a radioimmunotherapeutic treatment for marginal zone lymphoma; and Orphan Drug designation to a novel monoclonal antibody for...
A Visiting Resident Oncologist’s Training During the COVID-19 Pandemic
A visiting away elective is a resident’s designated time to visit another academic program to foster the growth of medical knowledge through patient care from the perspective of another health-care system and educational experience. The time dedicated to make this dream happen is grueling. First is ...
PICOS Score May Help Identify Patients With Brain Metastases at Risk of VTE
In a study published by Wolpert et al in the European Journal of Cancer, venous thromboembolic events (VTE) were reported in 12% of a cohort of patients with cancer that had metastasized to the brain. Researchers identified thrombogenicity of primary tumor, immobilization, chemotherapy, obesity,...
Expert Point of View: David Wise, MD and Celestia S. “Tia” Higano, MD, FACP
“GnRH antagonists have several advantages over GnRH agonists,” explained David Wise, MD, of Perlmutter Cancer Center at NYU Langone Health in New York. “There is no testosterone flare on initiation [as there is with leuprolide], no increase in cardiac toxicity, and faster onset of action. Currently ...
Addition of Rituximab to Standard Chemotherapy in Pediatric Patients With High-Risk, Mature B-Cell Non-Hodgkin Lymphoma
In a European Intergroup for Childhood Non-Hodgkin Lymphoma/Children’s Oncology Group phase III trial reported in The New England Journal of Medicine, Minard‑Colin et al found that the addition of rituximab to standard Lymphomes Malin B (also known as Lymphome Malin de Burkitt, or LMB) chemotherapy ...
Variant in Gene May Increase Cancer Risk in Those With Common TP53 R337H Mutations
Scientists studying a common TP53 R337H variant found among people of Brazilian descent discovered that a variant in the tumor-suppressor gene XAF1 increases cancer risk when combined with the inherited TP53 R337H mutation. These findings were published by Pinto et al in Science Advances. “We...
Long-Term Survival Outcomes With Different Durations of Adjuvant Imatinib for Gastrointestinal Stromal Tumors
In a 10-year follow-up of the phase III SSGXVIII/AIO trial reported in JAMA Oncology, Heikki Joensuu, MD, and colleagues found that 3 years vs 1 year of adjuvant treatment with imatinib was associated with superior overall survival among patients with high-risk gastrointestinal stromal tumors. The ...
Leaders of the PROMISE Study Address Racial Inequities in the United States
In 2018, researchers from Dana-Farber Cancer Institute launched a large, ambitious screening study called PROMISE (ClinicalTrials.gov identifier NCT03689595). The objectives of the study were to identify people with premalignant precursor conditions of multiple myeloma, understand the molecular...
I’m Not Too Young for Colorectal Cancer
The first symptoms I had of colorectal cancer—blood in my stool and abdominal pain—coincided with surgery I had to remove my appendix in the spring of 2017. My surgeon attributed the symptoms to the appendectomy and to the medications I received both before and after the surgery. In addition to...
AMA Board of Trustees Pledges Action Against Racism and Police Brutality
At a virtual Special Meeting of the American Medical Association (AMA) House of Delegates, the AMA Board of Trustees pledged action to confront systemic racism and police brutality. The AMA released the following statement that was approved at its meeting on June 5, 2020: The AMA recognizes that...
Capmatinib for Metastatic NSCLC With MET Exon 14 Skipping Mutation
On May 6, 2020, the oral mesenchymal-epithelial transition (MET) kinase inhibitor capmatinib was granted accelerated approval for the treatment of adult patients who have metastatic non–small cell lung cancer (NSCLC) with tumors that have a mutation that leads to MET exon 14 skipping, as detected...
NCI Renews Comprehensive Cancer Center Designation for Norris Cotton Cancer Center
The National Cancer Institute (NCI) has renewed its Cancer Center Support Grant to Dartmouth and Dartmouth-Hitchcock Norris Cotton Cancer Center (NCCC). The 5-year, $15.5 million grant will provide continued support for NCCC’s clinical care and research missions. NCI recognized the cancer center...
COVID-19 and Patients With Cancer: A Call to Action for Trainees
As oncology trainees, we develop skills to synthesize complex data and communicate this information with empathy as we accompany our patients through the trenches of a cancer diagnosis. With the current COVID-19 pandemic, an unprecedented layer of challenges has surfaced, as our patients who are...
Infographic, Commentaries in JCO Oncology Practice Examine Updates to ASCO’s Alternative Payment Model
A new infographic in the May 2020 print and online issues of JCO Oncology Practice (JCO OP) outlines paths to implementing ASCO’s Patient-Centered Oncology Payment (PCOP) model—an alternative payment model designed to support transformation in cancer care delivery and reimbursement while ensuring...
Penn Medicine Announces Appointment of Daniel Yoshor, MD, as Chair, Department of Neurosurgery
Neurosurgeon and neuroscientist Daniel Yoshor, MD, has been named Chair of the Department of Neurosurgery in the Perelman School of Medicine at the University of Pennsylvania and Vice President of Clinical Integration and Innovation for the University of Pennsylvania Health System in Philadelphia. ...
Polio and Cancer Survivor Mickie McGraw Channels the Power of Creative Arts to Heal Broken Bodies and Minds
GUEST EDITOR Dr. Abraham is Professor of Medicine, Lerner College of Medicine, and Chair of the Hematology and Medical Oncology Department at Taussig Cancer Institute, Cleveland Clinic. In this edition of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with pioneering art ...
